Full Press Release Details
Oncolytics Biotech Inc. Announces Details of 2017
Annual Meeting of Shareholders
CALGARY, April 27, 2017 /CNW/ - Oncolytics Biotech
Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that its 2017 Annual Meeting of Shareholders will be held
on Thursday, May 4th, 2017 at 4:00 pm ET (2:00 pm MT) at the Toronto Region Board of Trade located at First Canadian
Place, Suite 350, 77 Adelaide Street West, Toronto, Ontario.
Following the business portion of the meeting, Dr. Matt Coffey,
President and CEO of Oncolytics, will discuss recent progress in the development of REOLYSIN , including recent
randomized phase 2 metastatic breast cancer results as well as the detailed clinical development plan and specific initial registration
pathway for REOLYSIN.
A live audio webcast of Dr. Coffey's presentation will begin
at approximately 4:15 pm ET (2:15 pm MT) and be available at http://event.on24.com/r.htm?e=1415093&s=1&k=1D9EC98BC2D829CD19D1A85F7769DEAC
and on the company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners
log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible
approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, an immuno-oncology viral-agent, as a potential treatment for a variety
of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator
(IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study
in breast cancer, as well as studies in combination with checkpoint inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release and the presentation related thereto
contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's
expectations as to the success of its research and development programs in 2017 and beyond, the Company's planned operations, the
value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented
technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned
clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve
known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical
studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development
of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors
should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable
SOURCE Oncolytics Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/April2017/27/c5711.html
For further information: Oncolytics Investor & Media Contact:
Oncolytics Biotech Inc., Michael Moore, Vice President, Investor Relations & Corporate Communications, 858-886-7813, mmoore@oncolytics.ca;
AXON Media Contact: Marian Cutler, 914-701-0100 ext. 5361, mcutler@axon-com.com
CO: Oncolytics Biotech Inc.
CNW 07:00e 27-APR-17